A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors Article

Industry Collaboration

cited authors

  • Wong, Kwok-K.; Fracasso, Paula M.; Bukowski, Ronald M.; Lynch, Thomas J.; Munster, Pamela N.; Shapiro, Geoffrey I.; Jaenne, Pasi A.; Eder, Joseph P.; Naughton, Michael J.; Ellis, Matthew J.; Jones, Suzanne F.; Mekhail, Tarek; Zacharchuk, Charles; Vermette, Jennifer; Abbas, Richat; Quinn, Susan; Powell, Christine; Burris, Howard A.

authors

Publication Date

  • April 1, 2009

webpage

published in

category

start page

  • 2552

end page

  • 2558

volume

  • 15

issue

  • 7